This module reviews key aspects of research and clinical applications of liquid biopsies in cancer genomics, including the use of both circulating tumor cells (CTCs) and cell-free DNA (cfDNA). Topics include the clinical implications of liquid biopsies on screening, detection of mutations for therapy selection, disease prognosis and drug response and resistance. The module also describes the risks vs. benefits of applying liquid biopsies in cancer genomics, screening and treatment.
Upon successful completion of this module, participants should be better able to:
- Identify approaches to liquid biopsies and technologies used for isolation of CTCs and cfDNA
- Understand the potential clinical implications of liquid biopsies on cancer screening, detection of mutations for therapy selection, disease prognosis and drug response and resistance
- Distinguish between the risks and benefits of using liquid biopsies in clinical practice
Thank you for participating in this module. Click below to download the certificate.